Pharmanutra SpA

Pharmanutra SpA has a fully diluted share count of 9,575,183 shares, with no difference between basic and diluted shares outstanding, indicating no dilution risk from stock options or convertible instruments. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability metrics are not available in the current valuation snapshot, and no industry-specific preferred metrics are provided in the industry_config. As a result, a direct comparison to cohort medians for profitability and returns is not possible at this time. Pharmanutra's revenue concentration by segment and geography is not disclosed in the available data. The company operates in the pharmaceutical and personal care products industry, but no specific geographic or segment breakdown is provided in the input data. The company's growth trajectory is not quantified in the outlook section, and no numeric deltas are provided for the current or next fiscal year. Analysts have assigned a mean price target of 87.00 EUR, with a median of 87.00 EUR, and a mean recommendation of 1.67, indicating a generally positive outlook. The risk assessment indicates a low dilution risk, with no near-term dilution pressure identified. No specific dilution sources are disclosed in the input data, and no adjustments have been applied to the valuation metrics. No recent events, such as filings or transcripts, are provided in the input data to inform the company's current strategic or operational developments.